The mission of the Drug Discovery Program at OICR is to build a drug discovery program that can efficiently translate cancer-related academic discoveries into novel oncology therapies that will have a significant impact on the cancer patient population.
The Drug Discovery Program is comprised of three major functional areas: chemistry (medicinal, analytical and computational); drug delivery and formulation (focused on nanotechnology);and biology and screening support. Group members bring a collective depth and breadth of academic, pharmaceutical and biotech experiences and have a record of delivering high-quality leads and clinical candidates.
Under the leadership of Dr. Rima Al-awar, former Head in Discovery Chemistry at Eli Lilly & Co., the Drug Discovery Program has established key external collaborations with local institutions such as the University of Toronto, McMaster and Queen’s universities and other OICR Research Programs such as the Terry Fox-OICR Selective Therapies Program and the Cancer Stem Cell Program. The Drug Discovery Program continues to seek additional collaborations with recognized world leaders in the fields of oncology and cancer therapeutics with particular focus on novel targets and clinical applications.
Drug Discovery Program Fact Sheet
Lead Principal Investigator
Dr. Rima Al-awar
Director, Drug Discovery Program